- Home
- HE vs OCUL Comparison
HE vs OCUL Comparison
Compare HE & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | OCUL |
|---|---|---|
| Founded | 1891 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HE | OCUL |
|---|---|---|
| Price | $13.49 | $10.02 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $13.25 | ★ $23.56 |
| AVG Volume (30 Days) | 1.8M | ★ 3.1M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.32 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $3,086,896,000.00 | $1,990,000.00 |
| Revenue This Year | $7.00 | $7.93 |
| Revenue Next Year | $4.06 | $96.07 |
| P/E Ratio | $74.92 | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $10.54 | $6.23 |
| 52 Week High | $17.33 | $16.44 |
Technical Indicators
Market Signals| Indicator | HE | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 55.50 |
| Support Level | $13.14 | $9.24 |
| Resistance Level | $13.82 | $12.38 |
| Average True Range (ATR) | 0.30 | 0.50 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 67.28 | 40.21 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.